Netherlands· NL-ee857845d78d

Selexipag Teva 1600 microgram, filmomhulde tabletten

A selexipag product containing selexipag, registered in Netherlands by Teva GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC B01AC27

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about selexipagAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Selexipag is registered in 13 of 19 countries.

Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search selexipag products by name

Selexipag · ATC B01AC27

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selexipag costs, country by country.

Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Selexipag · price per daily dose (1.8 mg)

USD · FX 28 Sept 2026

IT Italy$1232.99
CH Switzerland$809.99

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: SELEXIPAG
Manufacturer: Teva GmbH
Country: Netherlands (NL)
ATC code: B01AC27
ATC class: Selexipag
Defined daily dose: 1.8 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
134320

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

237 interactions on record for selexipag.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check selexipag against other medicines How interaction checks work

Selexipag · interactions on record

237 records

1 severe
232 moderate
4 minor

Most severe, free to view

GemfibrozilC10AB04severe
PapaverineA03AD01moderate
MannitolA06AD16moderate
GlycerolA06AX01moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selexipag in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selexipag products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

Austria · Selexipag Ratiopharm
Cyprus · Selexipag Accord
Denmark · Selexipag Accord, Selexipag Stada
Estonia · Selexipag Stada
Spain · Selexipag Accord, Selexipag Stada
Greece · Xipeno
Croatia · Seleksipag Accord
Ireland · Selexipag Accord, Selexipag Clonmel
Iceland · Selexipag Stada, Uptravi
Italy · Selexipag Accord, Selexipag Eg
Liechtenstein · Uptravi
Lithuania · Selexipag Stada
Latvia · Selexipag Stada
Malta · Selexipag Clonmel
Norway · Selexipag Accord, Selexipag Stada
Poland · Selexipag, Selexipag Accord
Portugal · Selexipag Accord, Selexipag Teva
Sweden · Selexipag, Selexipag Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/60e93047-36bf-4499-9efd-0dce20409a0c
GET /v1/drugs/60e93047-36bf-4499-9efd-0dce20409a0c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h134320_smpc_en.pdf",
  "strength": null,
  "atc_label": "Selexipag",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg134320",
  "excipients": [
    "CALCIUMCARBONAAT (E 170)",
    "HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "MAÏSZETMEEL",
    "TALK (E 553b)"
  ],
  "substances": [
    "SELEXIPAG"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h134320_piluk.pdf",
  "authorised_at": "2026/01/06",
  "procedure_number": "SE/H/2666/008",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "134320",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about selexipag.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console